Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates

2011 ◽  
Vol 31 (5) ◽  
pp. 695-701 ◽  
Author(s):  
G. Samonis ◽  
S. Maraki ◽  
D. E. Karageorgopoulos ◽  
E. K. Vouloumanou ◽  
M. E. Falagas
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Multidrug Resistant ◽  
Clinical Isolates

scholarly journals A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa

2020 ◽  
Vol 16 ◽  
pp. 117693432093626
Author(s):  
Iván Darío Ocampo-Ibáñez ◽  
Yamil Liscano ◽  
Sandra Patricia Rivera-Sánchez ◽  
José Oñate-Garzón ◽  
Ashley Dayan Lugo-Guevara ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antibacterial Activity ◽  
Klebsiella Pneumoniae ◽  
Multidrug Resistant ◽  
Clinical Isolates ◽  
Health Concern ◽  
Wild Type ◽  
Cationic Antimicrobial Peptide ◽  
Promising Alternative ◽  
Resistant Strains

Infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa and Klebsiella pneumoniae are a serious worldwide public health concern due to the ineffectiveness of empirical antibiotic therapy. Therefore, research and the development of new antibiotic alternatives are urgently needed to control these bacteria. The use of cationic antimicrobial peptides (CAMPs) is a promising candidate alternative therapeutic strategy to antibiotics because they exhibit antibacterial activity against both antibiotic susceptible and MDR strains. In this study, we aimed to investigate the in vitro antibacterial effect of a short synthetic CAMP derived from the ΔM2 analog of Cec D-like (CAMP-CecD) against clinical isolates of K pneumoniae (n = 30) and P aeruginosa (n = 30), as well as its hemolytic activity. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of CAMP-CecD against wild-type and MDR strains were determined by the broth microdilution test. In addition, an in silico molecular dynamic simulation was performed to predict the interaction between CAMP-CecD and membrane models of K pneumoniae and P aeruginosa. The results revealed a bactericidal effect of CAMP-CecD against both wild-type and resistant strains, but MDR P aeruginosa showed higher susceptibility to this peptide with MIC values between 32 and >256 μg/mL. CAMP-CecD showed higher stability in the P aeruginosa membrane model compared with the K pneumoniae model due to the greater number of noncovalent interactions with phospholipid 1-Palmitoyl-2-oleyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (POPG). This may be related to the boosted effectiveness of the peptide against P aeruginosa clinical isolates. Given the antibacterial activity of CAMP-CecD against wild-type and MDR clinical isolates of P aeruginosa and K pneumoniae and its nonhemolytic effects on human erythrocytes, CAMP-CecD may be a promising alternative to conventional antibiotics.

scholarly journals Detection of KPC in Acinetobacter spp. in Puerto Rico

2009 ◽  
Vol 54 (3) ◽  
pp. 1354-1357 ◽  
Author(s):  
Iraida E. Robledo ◽  
Edna E. Aquino ◽  
María I. Santé ◽  
Jorge L. Santana ◽  
Diana M. Otero ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Puerto Rico ◽  
Klebsiella Pneumoniae ◽  
Acinetobacter Calcoaceticus ◽  
Multidrug Resistant ◽  
Beta Lactamase ◽  
Beta Lactam ◽  
Novel Variant ◽  
Acinetobacter Spp

ABSTRACT During an island-wide PCR-based surveillance study of beta-lactam resistance in multidrug-resistant (MDR) Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter calcoaceticus-baumannii complex isolates obtained from 17 different hospitals, 10 KPC-positive Acinetobacter isolates were identified. DNA sequencing of the bla KPC gene identified KPC-2, -3, and -4 and a novel variant, KPC-10. This is the first report of a KPC-type beta-lactamase identified in Acinetobacter species.

Identification of microorganisms by Fourier-transform infrared spectroscopy

2018 ◽  
pp. 50-57 ◽  
Author(s):  
A. Yu. Suntsova ◽  
R. R. Guliev ◽  
D. A. Popov ◽  
T. Yu. Vostrikova ◽  
D. V. Dubodelov ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Fourier Transform ◽  
Infrared Spectroscopy ◽  
Klebsiella Pneumoniae ◽  
Fourier Transform Infrared Spectroscopy ◽  
Infrared Spectra ◽  
Fourier Transform Infrared ◽  
Clinical Isolates

The need for novel techniques of rapid identification of pathogenic microorganisms arises from the massive spread of drug-resistant nosocomial strains and the emergence of centers for biohazard control. Fourier-transform infrared spectroscopy is a promising alternative to mass spectrometry as it is cost-effective, fast and suitable for field use. The aim of this work was to propose an algorithm for the identification of microorganisms in pure cultures based on the analysis of their Fourier transform infrared spectra. The algorithm is based on the automated principal component analysis of infrared spectra. Unlike its analogues described in the literature, the algorithm is capable of identifying bacteria regardless of the culture medium or growth phase. The training sample included the most prevalent causative agents of infections and sepsis in humans: Staphylococcus aureus (n = 67), Enterococcus faecalis (n = 10), Enterococcus faecium (n = 10), Klebsiella pneumoniae (n = 10), Escherichia coli (n = 10), Serratia marcescens (n = 10), Enterobacter cloacae (n = 10), Acinetobacter baumannii (n = 10), Pseudomonas aeruginosa (n = 10), and Candida albicans (n = 10). The model we built successfully passed a series of blind tests involving clinical isolates of 10 methicillin-resistant (MRSA) and 10 methicillin-sensitive (MSSA) Staphylococcus aureus strains as well as pair mixes of these cultures with clinical isolates of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae.

Discrepancy between colistin and polymyxin B susceptibility results among Escherichia coli and Klebsiella pneumoniae clinical isolates

2021 ◽  
Author(s):  
Serap Süzük Yıldız ◽  
Can Hüseyin Hekimoğlu ◽  
Zekiye Bakkaloğlu ◽  
Emine Alp
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Polymyxin B ◽  
Multidrug Resistant ◽  
Clinical Isolates ◽  
Resistant Bacteria ◽  
Major Error ◽  
E Coli ◽  
Microdilution Method ◽  
Broth Microdilution Method

AbstractThe selection of therapeutic agent to be used for the treatment of multidrug-resistant bacteria is a major concern. Polymyxin B use has been commenced in Turkey, although its clinical breakpoint is not listed in the EUCAST. This study aimed to determine the correlation between the MIC values of polymyxin B and colistin. A total of 505 isolates, including 122 isolates of Escherichia coli and 383 isolates of Klebsiella pneumoniae were included in the present study. All the isolates were assessed for colistin and polymyxin B using the broth microdilution method. The categorical agreement in the E. coli isolates was 98.4%, and the rate of very major error was 33.3%. The categorical agreement in the K. pneumoniae isolates was 99.5%, the rate of major error was 0.36%, and the rate of very major error was 0.98%. In the evaluation of the essential agreement, 1.6% error in E. coli and 2.3% error in K. pneumoniae were observed. It was concluded that polymyxin B should never be used in the treatment of the isolates reported as colistin-resistant, and if the MIC values are above 4 mg/L in E. coli and K. pneumoniae. Our results indicate importance of reporting both polymyxin B and colistin susceptibility results of clinical isolates.

scholarly journals Susceptibility of Selected Multi-Drug Resistant Clinical Isolates to Different Leaf Extracts of Senna alata

2018 ◽  
Vol 10 (1) ◽  
pp. 26-32
Author(s):  
Ibikunle Ibitayo ANIBIJUWON ◽  
Ifeoluwa Deborah GBALA ◽  
Bright Ifeanyi NNADOZIE ◽  
Olubukola IFAYEFUMI
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Aqueous Extract ◽  
Methanolic Extract ◽  
Ethanolic Extract ◽  
Clinical Isolates ◽  
Diffusion Method ◽  
Senna Alata

The present study evaluated the antibacterial effects of the methanolic, ethanolic and aqueous extracts of Senna alata leaves. The extracts were tested using agar well diffusion method against selected clinical isolates: Salmonella typhi, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Klebsiella pneumoniae. Antibiogram profile of the isolates deduced by disc diffusion method confirmed that the methanolic extract inhibited the growth of all tested organisms except for Klebsiella pneumoniae, which also showed no sensitivity to the ethanolic extract. There was no inhibition observed for the aqueous extract against all the tested organisms, indicating that the methanolic extract of the plant was more potent than the aqueous extract. Inhibitory activities were observed for gentamicin, ofloxacin and erythromycin against Staphylococcus aureus and Escherichia coli. No inhibitory activity was observed in all the antibiotics against Pseudomonas aeruginosa. In Klebsiella pneumoniae, inhibition was only observed in ofloxacin. The activity of both the methanolic and ethanolic extract of Senna alata was optimal under different concentrations, but gradually diminished as the concentration was adjusted. The activity of the plant extracts against the selected bacteria is an indication of the presence of broad spectrum bioactive compounds which could be explored in the therapy of bacterial infections.

scholarly journals Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

2015 ◽  
Vol 59 (8) ◽  
pp. 5029-5031 ◽  
Author(s):  
Amabel Lapuebla ◽  
Marie Abdallah ◽  
Olawole Olafisoye ◽  
Christopher Cortes ◽  
Carl Urban ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
New York ◽  
Pseudomonas Aeruginosa ◽  
New York City ◽  
Klebsiella Pneumoniae ◽  
York City ◽  
Multidrug Resistant ◽  
Gram Negative ◽  
Content Type ◽  
Added Benefit

ABSTRACTImipenem with relebactam was active againstEscherichia coli,Klebsiella pneumoniae, andEnterobacterspp., includingK. pneumoniaecarbapenemase (KPC)-producing isolates. Loss of OmpK36 in KPC-producingK. pneumoniaeisolates affected the susceptibility of this combination. Enhanced activity was evident againstPseudomonas aeruginosa, including isolates with depressedoprDand increasedampCexpression. However, the addition of relebactam to imipenem did not provide added benefit againstAcinetobacter baumannii. The combination of imipenem with relebactam demonstrated activity against KPC-producingEnterobacteriaceaeand multidrug-resistantP. aeruginosa.

scholarly journals In Vitro Double and Triple Bactericidal Activities of Doripenem, Polymyxin B, and Rifampin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli

2010 ◽  
Vol 54 (6) ◽  
pp. 2732-2734 ◽  
Author(s):  
Carl Urban ◽  
Noriel Mariano ◽  
James J. Rahal
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Acinetobacter Baumannii ◽  
Carbapenem Resistance ◽  
Polymyxin B ◽  
Multidrug Resistant ◽  
Carbapenem Resistant ◽  
Bactericidal Activities

ABSTRACT In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin were assessed against 20 carbapenem-resistant clinical isolates with different mechanisms of carbapenem resistance. Bactericidal activity was achieved in 90% of all bacteria assayed using combinations of polymyxin B, doripenem, and rifampin against five each of the carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli isolates studied. Combinations with these antibacterials may provide a strategy for treatment of patients infected with such organisms.

Sign in / Sign up

Export Citation Format

Share Document